LifeArc Ventures is the venture capital arm of LifeArc and invests globally in innovative, early-stage life sciences companies. LifeArc Ventures invests up to £15m (c.$20m) per company in Seed to Series B opportunities alongside leading global syndicates. The fund is long term capital which draws from LifeArc’s balance sheet derived mainly from Keytruda royalties. Since inception in 2020, the fund has invested in 20 companies including four new companies in 2025.
BioNJ’s BioPartnering Conference is the premier partnering event in New Jersey, where innovative companies go to meet investors and industry representatives.
As the Medicine Chest to the World, New Jersey is home to the world’s top biopharmaceutical companies and an ideal location for this conference for entrepreneurs to meet their next investor or partner. If you are interested in presentingyour company at the 2026 conference, please see details on the website, and be sure to submit your application no later than February 20, 2026.
The Expert Leader Programme is purposefully designed to support the unique demands of leading small-to-medium sized Life Science organisations in the United Kingdom. It is specifically for:
Life Science Nation (LSN) is excited to announce that the RESI (Redefining Every Stage of Investment) Europe Conference is moving to Lisbon, Portugal. RESI Europe will take place in person on March 23, 2026, at the EPIC SANA Lisboa Hotel (Av Eng. Duarte Pacheco, 15, 1070-100 Lisboa, Portugal), followed by two days of virtual partnering on March 24–25, 30-31, 2026.
We create a place where people can grow, be their best, be safe, and feel welcome, valued and included. We offer a competitive salary, an annual bonus based on company performance, healthcare and wellbeing programmes, pension plan membership, and shares and savings programme.
We embrace modern work practises; our Performance with Choice programme offers a hybrid working model, empowering you to find the optimal balance between remote and in-office work.
We are seeking an internationally recognised scientific leader to direct the Wellcome Sanger Institute’s Somatic Genomics Programme, one of our flagship research domains. This role offers the opportunity to define and deliver a bold, long-term scientific vision for understanding how somatic mutations arise, accumulate and shape human health across the lifespan.
At AstraZeneca, we're united by a bold ambition: to push the boundaries of science and deliver life-changing medicines to patients worldwide. As a global, science-led biopharmaceutical company, we transform pioneering research into breakthrough treatments across oncology, cardiovascular, respiratory, and rare diseases. Here, your talent will contribute to innovations that truly matter—helping us reimagine healthcare and create a healthier future for all!
Introduction to role:
Your new role - The Director of Marketing, Government, Funder & Non-profit (GFN) is a pivotal role responsible for driving pipeline growth and strengthening Digital Science’s brand across the region. Reporting to the VP of GFN Marketing, this role leads the development and execution of an integrated marketing strategy for public sector and non-profit audiences.
Metabolic instability is a key challenge in developing peptide therapeutics, and factors like rapid clearance and complex, multi-pathway biotransformation can further limit their effectiveness. Understanding and addressing these hurdles can unlock the full potential of peptide drugs, enabling them to reach challenging biological targets, support rational chemical design, and achieve clinical success. This webinar presents an integrated mechanism–analytics–design perspective to tackle these challenges and accelerate peptide drug discovery.